Red light therapy (RLT) helps manage hormonal conditions by delivering specific wavelengths that penetrate tissues to optimize cellular energy production in endocrine glands, reduce inflammation, and support healthy hormone synthesis.
For thyroid health, a 2025 study in Biomedicines found that combining photobiomodulation with supplements significantly improved thyroid function and reduced thyroid volume in Hashimoto's patients, with 820 nm light applied twice weekly for three weeks.
For reproductive health, a 2025 case report documented spontaneous conception and a healthy live birth in a woman with PCOS and endometriosis after five months of multiwavelength treatment.
For best results, use RLT 4-5 times weekly for thyroid and adrenal support, and 5-7 times weekly for reproductive concerns. Choose FDA-cleared devices with 630-670 nm red for superficial glands and 810-950 nm near-infrared for deeper penetration to ovaries, testes, and adrenals. Select larger panels for comprehensive coverage of bilateral glands, and ensure proper eye protection during use.
This think-piece details 15 hormonal concerns RLT helps, including low testosterone, thyroid disorders, polycystic ovary syndrome, menopause symptoms, premenstrual syndrome, estrogen dominance, cortisol imbalance, adrenal fatigue, infertility, growth hormone deficiency, insulin resistance, andropause, postpartum hormonal imbalance, thyroiditis (Hashimoto’s), and prolactin imbalance. It also outlines what you should know about using red light therapy for hormonal conditions, how it works for endocrine health, how to choose the right device, how frequently to use it, what precautions to take, whether you can use it at home, how long it takes to see improvements, and what other conditions red light therapy can treat.
The goal of the article is to educate readers with hormonal concerns about the different ways RLT can support their hormonal health and recovery.
1. Low Testosterone
Low testosterone (Low T) is a condition where the body fails to produce adequate levels of the primary male sex hormone. This potentially leads to reduced energy, libido, and fertility. Red light therapy (RLT) uses specific light wavelengths to stimulate mitochondrial function in Leydig cells (the testosterone-producing cells within the testes). This enhanced cellular energy (ATP production) may help these cells convert cholesterol into testosterone more efficiently.
Device Type
The process involves the targeted application of light to the testicular area using a wearable or panel device.
Device Settings
A 2024 animal study demonstrated that 7-day PBM treatment using 808 nm wavelength at 350 mW/cm² (delivering 42 J/cm²) significantly increased cerebrovascular testosterone concentration. A 2021 study on infertile mice found that PBM with an energy density of 0.03 J/cm² significantly increased serum testosterone levels and spermatogenic cells while reducing apoptosis. A 2025 study confirmed that laser therapy significantly increased serum testosterone levels in busulfan-treated mice.
For home use, devices delivering 630-660 nm red light and 810-850 nm near-infrared light at 10-50 mW/cm², applied for 10-15 minutes per session, 3-5 times weekly, are commonly recommended based on clinical parameters.
Before and After Results
Before treatment, individuals with Low T experience fatigue, reduced libido, and low energy. After PBM sessions, research shows significant increases in testosterone levels, with the 2025 study demonstrating notable increases in serum testosterone and improved sperm parameters. A 2024 systematic review of androgenic alopecia management confirms that low-level light treatment is recognised as an effective treatment option.
2. Thyroid Disorders (Hypothyroidism)
Hypothyroidism is a condition where the thyroid gland fails to produce sufficient thyroid hormones. It slows metabolism and causes fatigue, weight gain, and mood disturbances. Red light therapy (RLT) penetrates neck tissues and stimulates mitochondrial function in thyroid cells, potentially enhancing hormone production and reducing autoimmune inflammation.
Device Type
Apply light to the anterior neck region over the thyroid gland using a large panel device.
Device Settings
A 2023 clinical trial demonstrated significant improvements using an 820 nm near-infrared wavelength at 200 mW output power, delivering 32 J/cm² per point across 8 thyroid points, twice weekly for three consecutive weeks.
For home use, devices delivering 630-670 nm red light and 810-850 nm near-infrared at 10-50 mW/cm² applied for 10-15 minutes to the neck, 3-5 times weekly, are recommended based on clinical parameters.
Before and After Results
Before treatment, patients experience fatigue, weight gain, and require thyroid medication. After PBM sessions, research shows significant improvements: 95.7% of treatment participants reduced or discontinued thyroid medication, with 47% no longer requiring levothyroxine. A 2025 study documented significant reductions in thyroid volume, TSH, anti-TPO, anti-TG antibodies, and LT4 dosage, alongside weight loss and improved BMI. The 2023 trial confirmed restored thyroid function, improved anthropometric parameters, and decreased autoantibody levels.
A 2024 randomized controlled trial confirmed that PBM significantly improved oxidative stress biomarkers and quality of life in Hashimoto's patients. The 2020 study of 350 participants found PBM was 70 times more effective at increasing T3/T4 ratios and 15 times more effective at reducing levothyroxine dosage compared to supplements alone.
3. Polycystic Ovary Syndrome (PCOS)
Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by hormonal imbalances, irregular ovulation, and often infertility, affecting 5-20% of women of reproductive age. RLT improves ovarian function by reducing oxidative stress, inflammation, and apoptosis in ovarian tissues. The therapy enhances mitochondrial function, reduces oxidative damage, modulates microRNA expression, and decreases apoptosis in granulosa cells.
Device Type
Use a panel device on the lower abdominal area to target ovarian tissues.
Device Settings
A 2023 animal study investigating different LLLT dosages found that 2 J/cm² was the most potentially effective dose for PCOS treatment, significantly modulating hormone levels including luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone receptors. A 2017 comparative study using 630 nm (red) and 810 nm (near-infrared) lasers at 5 J/cm² energy density over 48 days found that near-infrared laser significantly increased ovarian activity and follicle production compared to the common fertility drug clomiphene.
In vitro research using a 640 nm wavelength demonstrated that PBM significantly improved oocyte health by increasing glutathione (GSH) and nucleus acetylation while regulating key microRNAs associated with PCOS pathogenesis.
Additional in vitro studies confirmed that PBM at 640 nm significantly increased oocyte maturation rates, reduced apoptosis markers, decreased reactive oxygen species, and improved fertilization potential in PCOS oocytes.
For home use, devices delivering 630-660 nm red light and 810-850 nm near-infrared at 10-50 mW/cm² applied for 10-15 minutes to the lower abdomen, 3-5 times weekly, may be considered based on clinical parameters.
Before and After Results
Before treatment, women with PCOS experience irregular ovulation, hormonal imbalances, and difficulty conceiving. After PBM sessions, research shows significant improvements: reduced ovarian cysts, increased healthy follicle development, improved oocyte maturation rates, and better hormonal profiles, including decreased testosterone and normalized LH levels.
A 2024 study on ovarian aging (relevant to PCOS-related ovarian dysfunction) found that PBM at 650 nm (4 J/cm²) effectively recovered sex hormone levels, increased primordial and growing follicles, improved angiogenesis, and decreased cell apoptosis while reducing oxidative stress and inflammation.
A 2018 study using 200 J/cm² confirmed that LLLT modulates follicular dynamics by regulating apoptosis and vascular stability, potentially improving oocyte quality.
A 2019 study demonstrated that PBM stimulation reduced plasma testosterone levels, increased progesterone levels, and decreased LH in PCOS-induced rats, while significantly reducing the number of ovarian cysts and increasing corpus luteum formation.
4. Menopause Symptoms
Menopause symptoms result from hormonal decline, causing hot flashes, mood changes, vaginal dryness, and genitourinary syndrome of menopause (GSM), including dyspareunia and urinary issues. RLT stimulates cellular energy, reduces inflammation, and promotes tissue regeneration in affected areas. The therapy works by stimulating mitochondrial activity, reducing oxidative stress, and promoting tissue regeneration in urogenital tissues.
Device Type
The treatment process involves applying specific wavelengths to the vulvovaginal region or lower abdomen using a flexible device that can mold to the user’s body.
Device Settings
A 2024 study protocol utilizes an 808 nm diode laser at 4J per point, 100mW power, across 8 vulvar sites weekly for four weeks. A 2025 study using a 1470 nm diode laser monthly for three months, combined with pelvic floor therapy, demonstrated significant improvements.
A 2024 prospective study of post-menopausal women undergoing three diode laser sessions reported significant improvements: Vaginal Health Index Score increased from 12 to 19.27 at 6 months, vaginal dryness decreased from 7.72 to 3.72, burning from 6.00 to 1.90, and dyspareunia from 8.09 to 3.90, with FSFI-6 sexual function scores improving from 12.27 to 19.30.
A 2023 study on cancer-treatment-induced menopause reported that 72% of patients felt better or much better after at least 6 PBM sessions, with a median improvement estimated at 65%.
For home use, devices delivering 630-660 nm red light and 810-850 nm near-infrared at 10-50 mW/cm² applied for 10-15 minutes to the lower abdomen or vulvar region, 3-5 times weekly, may be considered based on clinical parameters.
Before and After Results
Before treatment, women experience vaginal dryness, burning, painful intercourse, and reduced quality of life. After RLT sessions, research shows significant symptom relief, improved vaginal health, enhanced sexual function, and better overall quality of life without serious adverse events. A 2019 review confirms that PBM is safe and appears efficacious for treating GSM based on preliminary evidence.
5. PMS (Premenstrual Syndrome)
Premenstrual syndrome (PMS) is a group of physical and emotional symptoms, including mood swings, irritability, bloating, and fatigue, that occur during the luteal phase of the menstrual cycle. Red light therapy, delivered as photic stimulation, offers a non-invasive approach to alleviate these symptoms, potentially by influencing circadian rhythms and neuroendocrine function.
Device Type
The process involves daily exposure to flickering red light from a panel device or body-contouring model.
Device Settings
A 1997 open study of 17 women with severe, long-standing premenstrual syndrome used photic stimulation with a flickering red light every day for up to four menstrual cycles. The protocol involved daily sessions throughout the treatment period, though specific duration and intensity parameters were not detailed in the abstract.
For home use, bright light therapy boxes delivering broad-spectrum light have been studied, with active treatment using 10,000 lx cool-white fluorescent light compared to placebo 500 lx dim red light in a 1999 crossover study.
Devices delivering red spectrum light in the 630-660 nm range at 10-50 mW/cm² applied for 30 minutes daily during symptomatic phases may be considered, though standardized protocols for PMS specifically require further development.
Before and After Results
Before treatment, patients experience significant mood disturbances, physical discomfort, and reduced quality of life during the luteal phase. After completing photic stimulation therapy, results were remarkable: prospectively recorded median luteal symptom scores were reduced by 76%, with clinically and statistically significant reductions for depression, anxiety, affective lability, irritability, poor concentration, fatigue, food cravings, bloating, and breast pain. Notably, 12 of the 17 patients (71%) no longer met criteria for premenstrual syndrome after treatment.
A 1999 randomized controlled trial confirmed that active bright light therapy significantly reduced depression and pre-menstrual tension scores during the symptomatic luteal phase compared to baseline, while placebo dim red light did not. The therapy works by influencing circadian melatonin rhythms, which are often disrupted in PMS patients. After light therapy in premenstrual dysphoric disorder subjects, melatonin onset and offset times shifted appropriately, with associated mood improvements.
6. Estrogen Dominance
Estrogen dominance is a condition characterized by an excess of estrogen relative to progesterone, potentially contributing to menstrual irregularities, PMS, and fertility challenges. Red light therapy (RLT) may help rebalance estrogen dominance by influencing circadian rhythms and pituitary hormone secretion, which regulate the menstrual cycle and ovulation. The therapy works by influencing circadian melatonin rhythms, which in turn modulate the hypothalamic-pituitary-ovarian axis.
Device Type
The process involves timed light exposure to influence neuroendocrine function through LED panels placed on the lower abdomen or pelvic area.
Device Settings
A 2007 controlled crossover trial demonstrated that morning exposure to bright light (4,300 lux for 45 minutes) during the follicular phase significantly increased follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, while promoting follicle growth and increasing ovulation rates.
A 1990 clinical trial found that 100-watt bedside light exposure from days 13-17 of the menstrual cycle shortened long cycles from 45.7 to 33.1 days, while dim red placebo light had no effect.
For home use, devices delivering 630-660 nm red light at 10-50 mW/cm² applied for 30-45 minutes daily during the follicular phase may be considered based on these phototherapy parameters.
Before and After Results
Before treatment, women with estrogen dominance often experience long, irregular cycles and ovulatory dysfunction. After timed light exposure, research shows normalized cycle length, improved ovulation rates, and enhanced secretion of pituitary reproductive hormones that help balance the estrogen-progesterone ratio.
7. Cortisol Imbalance (Chronic Stress)
Cortisol imbalance, often resulting from chronic stress, disrupts the body's hypothalamic-pituitary-adrenal (HPA) axis, leading to elevated cortisol levels that can impair sleep, mood, and metabolic health. RLT modulates this stress response at the cellular level.
Device Type
Apply specific wavelengths through a panel to target tissues, including the mid-back area and the back of the neck.
Device Settings
A 2019 animal study demonstrated that transcranial PBM using 810 nm near-infrared laser significantly decreased serum cortisol levels in chronically stressed mice. The protocol delivered energy doses of 4, 8, and 16 J/cm² with an output power of 200 mW and a power density of 4.75 W/cm², applied three times weekly for three weeks. The 8 J/cm² dose produced the maximum anti-anxiety and cortisol-lowering effects.
A 2022 clinical trial protocol is investigating vascular PBM using 660 nm red light at 100 mW power, applied to the radial artery for 30 minutes per session, twice weekly for 10 sessions, with salivary cortisol as a primary outcome measure.
For home use, devices delivering 630-660 nm red light and 810-850 nm near-infrared at 10-50 mW/cm² applied for 10-20 minutes per session, 3-5 times weekly, may be considered based on these parameters.
Before and After Results
Before treatment, individuals with chronic stress experience elevated cortisol, anxiety, sleep disturbances, and reduced quality of life. After PBM sessions, research demonstrates a significant reduction in serum cortisol levels and improved behavioral outcomes in stress models. A 2026 randomized controlled trial using bright light therapy (related phototherapy) also showed a significant reduction in cortisol mesor after a 2-week intervention.
A 2020 study on light therapy in cancer survivors showed moderate effects on cortisol slope steepness and total cortisol output. The therapy works by modulating the HPA axis, reducing inflammation, and potentially increasing serotonin while decreasing nitric oxide levels in brain regions involved in stress response.
8. Adrenal Fatigue
Adrenal fatigue is a term used to describe a collection of non-specific symptoms such as body aches, fatigue, and sleep disturbances, which are theoretically linked to a deficiency in adrenal cortex function. Research suggests that low-intensity laser irradiation can directly stimulate the adrenal cortex to improve its functional status.
Device Type
Use an RLT panel device and apply specific wavelengths to the skin projection region of the adrenal glands.
Device Settings
A 1990 animal study demonstrated that direct helium-neon laser irradiation of the adrenal glands significantly increased corticosteroid function, as evidenced by increased capillary blood volume and nuclear mass in the adrenal cortex. A 2006 clinical trial on bronchial asthma patients found that exposing the adrenal projection region to infrared laser radiation normalized blood hydrocortisone levels, improved clinical symptoms, and reduced disease duration. A 1983 study also confirmed that diffuse light from helium-neon lasers affected glucocorticoid functions of the adrenal cortex.
For home use, devices delivering 630-660 nm red light or 810-850 nm near-infrared at 10-50 mW/cm² applied for 10-15 minutes to the lower back (adrenal region), 3-5 times weekly, may be considered based on these parameters.
Before and After Results
Before treatment, individuals may experience fatigue, lowered cortisol, and reduced adrenal function. After laser therapy sessions, research shows normalization of blood hydrocortisone levels, improved functional status of the adrenal cortex, and better clinical outcomes. A 2015 review confirmed that the skin's neuroendocrine system communicates with the central hypothalamic-pituitary-adrenal (HPA) axis, suggesting light-based therapies can influence systemic hormone levels.
9. Infertility (Hormonal Cause)
Hormonal infertility refers to difficulty conceiving due to endocrine imbalances that disrupt ovulation, sperm production, or the hormonal environment required for conception. Red light therapy can improve fertility outcomes by enhancing mitochondrial function, reducing oxidative stress, and modulating hormonal pathways in reproductive tissues.
The therapy works by stimulating mitochondrial ATP production, reducing reactive oxygen species, modulating nitric oxide levels, and regulating gene expression in reproductive tissues.
Device Type
The treatment involves using LED panels to apply specific wavelengths to reproductive organs or gametes.
Device Settings
A 2025 case report of a woman with PCOS, endometriosis, and low ovarian reserve, who failed to conceive naturally for five years and had one unsuccessful IVF cycle, received PBM using multiple wavelengths between 600-1000 nm applied during the follicular stage at weekly or biweekly intervals over five months, resulting in spontaneous conception and a healthy live birth.
For male infertility, a 2025 study on asthenozoospermic sperm demonstrated that 810 nm irradiation produced the most marked improvement in mitochondrial energetic status and sperm motility, while 635 nm exposure led to decreased cellular energy levels. A 2024 animal study using 0.03 J/cm²/sec laser irradiation every other day for 35 days significantly increased serum testosterone levels, testicular cell numbers, and sperm parameters in busulfan-treated mice.
A 2023 bovine study using 660-665 nm red light for 10 minutes during oocyte maturation significantly improved blastocyst development rates and increased blastocyst cell numbers. For home use, devices delivering 630-660 nm red light and 810-850 nm near-infrared at 10-50 mW/cm² applied for 10-15 minutes to the lower abdomen (female) or testes (male), 3-5 times weekly, may be considered based on clinical parameters.
Before and After Results
Before treatment, individuals experience prolonged infertility, hormonal imbalances, and poor gamete quality. After PBM sessions, research shows improved oocyte maturation, enhanced sperm motility, increased blastocyst development rates, normalized hormone levels, and successful conception outcomes.
10. Growth Hormone Deficiency
Growth hormone deficiency (GHD) is a medical condition where the pituitary gland fails to produce sufficient growth hormone, potentially affecting growth, metabolism, and overall health in both children and adults. Red light therapy (RLT) potentially impacts growth hormone production and its downstream effectors by directly targeting pituitary cells and promoting the release of growth factors.
The therapy stimulates mitochondrial cytochrome c oxidase, increasing ATP production and modulating gene expression related to growth hormone synthesis and release.
Device Type
Apply a panel-like device with specific wavelengths to relevant areas, such as the pituitary region or acupuncture points associated with growth.
Device Settings
A 2009 study demonstrated that exposing rat pituitary cells to 670 nm red light at 50 mW/cm² intensity and 4 J/cm² energy density significantly up-regulated growth hormone release by breaking down intracellular, oligomeric GH stores. A 2018 animal study using laserpuncture with a 635-680 nm/5 mW red laser at 0.3 J/cm² for 60 seconds on specific acupoints for 15 days markedly increased serum concentrations of insulin-like growth factor-1 (a key downstream mediator of GH action) in adolescent rats.
A 2013 study also confirmed that laser acupuncture with similar parameters significantly increased bone growth rate and growth plate height in adolescent rats.
Additional research confirms that LLLT at 685 nm and 2 J/cm² significantly increases IGF-1 release from human gingival fibroblasts.
For home use, devices delivering 630-680 nm red light at 10-50 mW/cm² applied for 10-15 minutes per session, 3-5 times weekly to the lower skull base (pituitary region) or relevant acupoints may be considered based on these parameters.
Before and After Results
Before treatment, individuals with growth hormone deficiency may experience short stature, reduced muscle mass, or metabolic disturbances. After PBM or laserpuncture sessions, research shows significantly increased serum IGF-1 concentrations, enhanced growth plate activity, and improved longitudinal bone growth in animal models. In vitro studies confirm consistent IGF-1 release from fibroblasts and osteoblasts following irradiation.
11. Insulin Resistance / Metabolic Syndrome
Insulin resistance is a condition where cells fail to respond effectively to insulin, often leading to metabolic syndrome: a cluster of conditions including elevated blood sugar, abdominal obesity, and abnormal cholesterol levels that increase cardiovascular and diabetes risk. Red light therapy improves insulin sensitivity by enhancing mitochondrial function and reducing inflammation in metabolic tissues.
Device Type
Applying specific wavelengths to target areas such as the abdomen or skeletal muscles using a flexible RLT panel or belt.
Device Settings
A 2024 in vitro study demonstrated that combined red and near-infrared PBM at 660 nm and 850 nm with energy doses of 4 or 8 J/cm² significantly reversed insulin resistance in muscle cells by improving intracellular insulin signaling (Akt phosphorylation) and reducing stress kinase activation (JNK). A 2025 randomized controlled trial in women with obesity used whole-body PBM with 633-660 nm red light and 850-940 nm near-infrared at an intensity of approximately 50 mW/cm² for 12 minutes per session, finding a significant +9.3% increase in resting energy expenditure post-treatment.
For home use, devices delivering 630-660 nm red light and 810-850 nm near-infrared at 10-50 mW/cm² applied for 10-15 minutes to the abdomen or lower back, 3-5 times weekly, may be considered based on clinical parameters.
Before and After Results
Before treatment, individuals exhibit elevated fasting glucose, insulin resistance, and metabolic dysfunction. After PBM sessions, improvements include improved insulin signaling in muscle cells, enhanced mitochondrial function, reduced inflammatory markers, and increased resting energy expenditure.
A 2024 review of 87 clinical trials confirmed PBM-induced reductions in fasting and postprandial glycemia without increased hypoglycemic risk.
A 2023 completed clinical trial of type 2 diabetic patients receiving low-level laser therapy reported decreased fasting blood glucose levels and improved fasting C-peptide, with an acute lowering response of blood glucose by 22.7 mg/dl in the laser group compared to controls.
12. Andropause (Male Menopause)
Andropause, often called male menopause, refers to the age-related decline in testosterone and other hormones in men, after age 40, leading to symptoms such as fatigue, reduced libido, and mood disturbances. Red light therapy (RLT) supports hormonal balance by stimulating testicular Leydig cells and modulating pituitary hormone secretion.
Device Type
An RLT panel device with specific wavelengths shows results eventually to the testicular area or lower back.
Device Settings
A 1996 clinical study examining low-intensity infrared laser therapy in men aged 40-65 with climacteric disorders (andropause) demonstrated significant hormonal improvements. The infrared laser therapy produced a response in men as evidenced by normalization of FSH, LH levels, and elevation of sex steroid hormones. A 2024 study on dual-wavelength LED therapy (620 and 660 nm) demonstrated that red light stimulates nitric oxide production, which plays a role in hormonal signaling pathways.
A 2023 in vitro study on human dermal papilla cells found that red light at 8 mW/cm² was most effective in promoting cellular growth and modulating key signaling pathways, including those involved in hormone response.
For home use, devices delivering 630-660 nm red light and 810-850 nm near-infrared at 10-50 mW/cm² applied for 10-15 minutes to the lower abdomen/testicular area, 3-5 times weekly, may be considered based on these parameters.
Before and After Results
Before treatment, men experience fatigue, reduced libido, mood changes, and hormonal imbalances associated with aging. After RLT sessions, the common results include normalized FSH and LH levels, elevated sex steroid hormones, and improved symptoms associated with climacteric disorders.
A 2021 review of LLLT clinical applications confirmed that photobiomodulation enhances mitochondrial ATP production, cell signaling, and growth factor synthesis while attenuating oxidative stress, which are mechanisms relevant to supporting hormonal health during aging.
13. Postpartum Hormonal Imbalance
Postpartum hormonal imbalance refers to the dramatic fluctuations in estrogen, progesterone, and other hormones following childbirth, which can contribute to mood disturbances, fatigue, and lactation difficulties. RLT supports hormonal recovery by stimulating mitochondrial cytochrome c oxidase, enhancing cellular energy, reducing inflammation, and promoting tissue healing during the postpartum period.
Device Type
Use a flexible RLT device for application to specific wavelengths to relevant areas such as the breasts, perineum, or lower abdomen.
Device Settings
A 2009 randomized controlled trial of women after cesarean section used 980 nm (100 mW, 3.3 J/cm², total energy 60 J) and 650 nm (30 mW, 1.5 J/cm², total energy 27 J) to the incision line, plus intravenous laser irradiation at 2.5 mW and 650 nm for 15 minutes on three consecutive postoperative days. The study found that LLLT after cesarean section does not compromise blood prolactin levels or lactation status, with no statistically significant difference between treated and control groups.
A 2019 randomized controlled trial on postnatal scanty milk secretion used a low-power He-Ne laser on both breasts and found that serum prolactin was significantly elevated in the laser group compared to controls, with corresponding increases in infant weight and breastfeeding satisfaction. A 2021 quasi-experimental study on postpartum women exposed to long-wavelength artificial light at night found significant effects on melatonin levels, suggesting light therapy can influence circadian hormone regulation during the postpartum period.
For home use, devices delivering 630-660 nm red light and 810-850 nm near-infrared at 10-50 mW/cm² applied for 10-15 minutes per session, 3-5 times weekly to the lower abdomen, breasts, or perineal area may be considered based on clinical parameters.
Before and After Results
Before treatment, postpartum women often experience hormonal fluctuations, fatigue, mood changes, and lactation difficulties. After RLT sessions, research shows maintained or improved prolactin levels, enhanced milk secretion, better wound healing, and potential support for circadian rhythm regulation. A 2024 conference abstract highlighted that PBM increases cellular ATP through mitochondrial stimulation, reducing postpartum depletion and accelerating recovery from labor and birth. A 2025 narrative review confirms that light therapy shows benefit for postpartum depression, which is closely linked to hormonal fluctuations.
14. Thyroiditis (Hashimoto’s)
Hashimoto’s thyroiditis is a chronic autoimmune disorder where the immune system attacks the thyroid gland, leading to inflammation and hypothyroidism. Red light therapy modulates immune response, reduces thyroid autoantibodies, and improves gland function in Hashimoto’s. The therapy works by stimulating mitochondrial activity, reducing oxidative stress, and modulating autoimmune inflammation.
Device Type
Through a light panel or a flexible wrap, apply specific wavelengths to the anterior neck over the thyroid gland.
Device Settings
A 2025 study of 98 females used an 820 nm wavelength at 200 mW output power, 32 J/cm² energy density per point, applied to 8 thyroid points for 20 seconds each, twice weekly for three weeks. A 2024 clinical trial protocol employed an 850 nm continuous wave at 100 mW output, 1.43 W/cm² power density, and 28.57 J/cm² energy density, marking 8 target points on the thyroid gland under ultrasound guidance.
For home use, devices delivering 630-850 nm at 10-50 mW/cm² applied for 10-15 minutes to the neck, 3-5 times weekly, may be considered based on clinical parameters.
Before and After Results
Before treatment, patients experience fatigue, elevated thyroid antibodies (anti-TPO, anti-TG), and require levothyroxine therapy. After PBM sessions, research shows significant improvements: reduced TSH, anti-TPO, and anti-TG antibody levels, decreased levothyroxine dosage, thyroid volume normalization, and improved anthropometric parameters, including weight loss and reduced BMI. A 2024 study confirmed significant improvement in oxidative stress biomarkers and quality of life, with enhanced glutathione levels in the active treatment group.
15. Prolactin Imbalance
Prolactin imbalance refers to abnormal levels of the hormone prolactin, which can cause lactation disturbances, menstrual irregularities, and fertility issues in both women and men. RLT modulates prolactin secretion by influencing neuroendocrine pathways and supporting pituitary function. The therapy works by influencing hypothalamic-pituitary regulation of prolactin secretion through photobiomodulation of neuroendocrine pathways.
Device Type
Utilize an RLT panel device in relevant areas such as the pituitary region or breasts.
Device Settings
A 2009 randomized controlled trial of women after cesarean section used 980 nm (100 mW, 3.3 J/cm²) and 650 nm (30 mW, 1.5 J/cm²) to the incision line plus intravenous laser irradiation, finding that LLLT does not compromise blood prolactin levels or lactation status. A 2019 randomized controlled trial on postnatal scanty milk secretion used a low-power He-Ne laser on both breasts and found serum prolactin was significantly elevated in the laser group compared to controls, with corresponding increases in infant weight and breastfeeding satisfaction. A 1986 animal study demonstrated that red light can significantly affect prolactin secretion, particularly during nocturnal and prediurnal periods, varying with physiological state and time of day.
For home use, devices delivering 630-660 nm red light and 810-850 nm near-infrared at 10-50 mW/cm² applied for 10-15 minutes per session, 3-5 times weekly to the lower skull base (pituitary region) or breasts may be considered based on clinical parameters.
Before and After Results
Before treatment, individuals may experience insufficient lactation, menstrual irregularities, or hyperprolactinemia symptoms. After RLT sessions, you notice significantly elevated prolactin levels in cases of scanty milk secretion. A 1985 study on newborn phototherapy found that 48 hours of continuous light exposure did not impair pituitary function, including prolactin-related pathways. The effect of red light on prolactin varies with physiological state and timing, indicating that optimal protocols may need to be personalized based on the specific nature of the imbalance.
What should You Know about Using Red Light Therapy for Hormonal Conditions?
Before incorporating red light therapy into your wellness routine for hormonal balance, it is important to grasp how light interacts with endocrine tissues, what to look for when choosing a device, how often to apply it, and the safety protocols that protect you during use. You should understand whether at-home treatment is practical, how quickly you might notice shifts in your symptoms, and the full spectrum of hormonal issues (from thyroid dysfunction to reproductive imbalances) that this therapy may help address.
How does Red Light Therapy Work for Hormonal Conditions?
Red light therapy works for hormonal conditions by delivering specific wavelengths of red and near-infrared light that penetrate the skin and are absorbed by cells within the endocrine glands. This photon energy is taken up by cytochrome c oxidase in the mitochondria, which boosts the production of adenosine triphosphate (ATP). The surge in cellular energy enhances the secretory activity of glandular cells, allowing them to produce and regulate hormones like cortisol, testosterone, estrogen, and thyroid hormones more efficiently.
Additionally, photobiomodulation acts as a powerful modulator of oxidative stress and inflammation, which are common disruptors of hormonal balance. By improving local blood flow and reducing inflammation in the glands themselves, the therapy helps restore the delicate feedback loops of the endocrine system.
How to Choose the Right Red Light Device for Hormonal Conditions?
To choose the right red light device for hormonal conditions, you must look beyond general wellness panels and select equipment designed to reach deep-seated glands, prioritizing regulatory clearance and specific wavelength penetration. Below is a more detailed description:
- Prioritize FDA clearance or CE marking. Ensure the device has regulatory certification to guarantee it meets safety and manufacturing standards for therapeutic use.
- Match wavelength to gland location. Use red light 630-670 nm for superficial glands like the thyroid and parathyroid. Use near-infrared 810-950 nm for deeper penetration required to reach the ovaries, testes, pancreas, and adrenal glands located behind the viscera.
- Select appropriate applicator type. For thyroid and parathyroid health, choose flexible pads or panels that can be contoured to the neck. For adrenal fatigue or reproductive health, larger panels that can cover the lower back or abdominal area are necessary. For localized testicular therapy, specialized wands or probes with lower power settings may be preferred.
- Ensure sufficient power output. Verify that the device delivers a therapeutic irradiance (measured in mW/cm²) capable of penetrating tissue depth to reach the target gland, as supported by clinical endocrine studies.
- Look for large treatment areas. Because hormonal glands are often bilateral (like adrenals and ovaries) or spread out (like the thyroid), a device with a large panel or multiple diodes ensures comprehensive coverage in a single session.
How Frequently should You Use Red Light Therapy for Hormonal Conditions?
For hormonal conditions, use red light therapy 4 to 7 times weekly, depending on the specific issue. For instance, adrenal & thyroid needs 4-5 sessions/week for 4-6 weeks, then 2-3 times weekly for maintenance. Reproductive (PCOS/low testosterone) requires 5-7 sessions/week during the initial phase. Insulin resistance requires 5-6 sessions/week for consistent support.
What Precautions should You take Before Red Light Therapy?
Before starting red light therapy for hormonal conditions, you must take the following precautions due to the potent nature of the endocrine system.
- Consult an endocrinologist or healthcare provider for a proper diagnosis, especially for conditions like hyperthyroidism, adrenal insufficiency, or hormone-sensitive cancers. Light therapy may stimulate activity in tissues where suppression is actually needed.
- Always wear wavelength-specific protective goggles, even when treating the lower back or abdomen. Bright light exposure can indirectly affect the pineal gland and circadian rhythms, which govern hormonal cycles.
- Check device certification and use only FDA-cleared products to ensure wavelength stability and output accuracy.
- Avoid direct irradiation of known cancerous tissues or masses without oncologist approval, as the proliferative effects of light are contraindicated in active malignancies.
- Monitor medication interactions. Use caution if you are taking photosensitizing medications (e.g., certain antibiotics, retinoids, or St. John's Wort) as they can increase the risk of tissue damage.
- Be mindful of treatment timing. Light exposure can influence cortisol and melatonin. Avoid stimulating the adrenals with near-infrared light too close to bedtime, as it may disrupt sleep cycles.
Can You Take Red Light Therapy at Home?
Yes, you can safely use red light therapy at home to support hormonal health, provided you invest in a device capable of reaching the depth of your target glands and adhere to strict safety protocols. But to ensure maximum safety, here is what you need:
- An FDA-cleared or CE-marked home device with sufficient power output (often panel-based) to penetrate to the depth of the adrenals, ovaries, or thyroid.
- Wavelength-specific protective goggles to protect your eyes and maintain natural circadian hormone function.
- A proper diagnosis from a healthcare provider is necessary to ensure that stimulating a specific gland is appropriate for your condition.
- The manufacturer's instruction manual provides proper usage guidelines, particularly regarding distance from the skin and duration.
- A device with cooling fans or heat management is used when treating the scrotal area for testicular health. Excessive heat can be counterproductive to sperm production.
How Long does it take to See Improvements?
Improvements from red light therapy for hormonal conditions typically appear within 2 to 12 weeks, depending on the specific gland and the chronicity of the imbalance. Some examples are as follows:
- Thyroid: Initial energy improvements in 2-4 weeks; blood marker changes in 6-8 weeks.
- Adrenal Fatigue: Symptom relief (e.g., afternoon crashes) in 3-5 weeks.
- Menstrual Cycle & PCOS: Regulation often requires 6-12 weeks to influence a full follicular cycle.
- Testosterone: Subjective effects (libido, energy) in 3-4 weeks; measurable hormonal changes around 8 weeks.
- Insulin Sensitivity: Metabolic marker improvements typically take 8-12 weeks.
What Other Conditions Can Red Light Therapy Treat?
Besides hormonal conditions, red light therapy also treats a wide range of other health issues, leveraging its core mechanisms of reducing inflammation, accelerating tissue repair, and improving circulation, including the following:
- Skin rejuvenation and wound healing
- Hair growth restoration
- Muscle recovery and sports performance
- Joint pain and arthritis
- Neuropathic pain and neuropathy
- Dental pain and oral mucositis
- Traumatic brain injury and cognitive function
- Gut health and digestive disorders
- Seasonal affective disorder (SAD)
- Lymphedema and lymphatic drainage
References
- https://www.mdpi.com/2304-6732/12/10/1021
- https://www.mdpi.com/2227-9059/13/7/1555
- https://advancestudy.org/does-red-light-therapy-work-for-testosterone/
- https://advancestudy.org/does-red-light-boost-testosterone/
- https://pubmed.ncbi.nlm.nih.gov/38421088/
- https://pubmed.ncbi.nlm.nih.gov/33825170/
- https://pubmed.ncbi.nlm.nih.gov/40351155/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11499963/figre/F4/
- https://pubmed.ncbi.nlm.nih.gov/38852607/
- https://advancestudy.org/can-you-use-red-light-therapy-if-you-have-hypothyroidism/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10455109/?utm
- https://www.lasermedicine.co.uk/laser-therapy-for-hashimoto-thyroiditis/#main
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12292235/
- https://pubmed.ncbi.nlm.nih.gov/38628043/
- https://pubmed.ncbi.nlm.nih.gov/30897401/
- https://pubmed.ncbi.nlm.nih.gov/37544939/
- https://pubmed.ncbi.nlm.nih.gov/28801854a /
- https://pubmed.ncbi.nlm.nih.gov/39051004/
- https://pubmed.ncbi.nlm.nih.gov/37583503/
- https://pubmed.ncbi.nlm.nih.gov/39276447/
- https://pubmed.ncbi.nlm.nih.gov/30500339/
- https://pubmed.ncbi.nlm.nih.gov/39621728/
- https://pubmed.ncbi.nlm.nih.gov/40978597/
- https://pubmed.ncbi.nlm.nih.gov/39470875/
- https://pubmed.ncbi.nlm.nih.gov/37183056/
- https://pubmed.ncbi.nlm.nih.gov/31210575/
- https://pubmed.ncbi.nlm.nih.gov/15511777/
- https://pubmed.ncbi.nlm.nih.gov/9104690/
- https://pubmed.ncbi.nlm.nih.gov/10482337/
- https://pubmed.ncbi.nlm.nih.gov/17290302/
- https://pubmed.ncbi.nlm.nih.gov/2243890/
- https://pubmed.ncbi.nlm.nih.gov/30883832/
- https://clinicaltrials.gov/study/NCT05415163
- https://pubmed.ncbi.nlm.nih.gov/41756577/
- https://pubmed.ncbi.nlm.nih.gov/33070045/
- https://pubmed.ncbi.nlm.nih.gov/2397306/
- https://pubmed.ncbi.nlm.nih.gov/17019956/
- https://pubmed.ncbi.nlm.nih.gov/6654130/
- https://pubmed.ncbi.nlm.nih.gov/25964265/
- https://pubmed.ncbi.nlm.nih.gov/40427680/
- https://www.publish.csiro.au/rd/Fulltext/RDV36N2AB208
- https://www.ncbi.nlm.nih.gov/books/NBK425701/
- https://pubmed.ncbi.nlm.nih.gov/19191355/
- https://pubmed.ncbi.nlm.nih.gov/29216780/
- https://pubmed.ncbi.nlm.nih.gov/24019980/
- https://pubmed.ncbi.nlm.nih.gov/18622623/
- https://pubmed.ncbi.nlm.nih.gov/40507946/
- https://pubmed.ncbi.nlm.nih.gov/39398538/
- https://air.unimi.it/handle/2434/1190439
- https://pubmed.ncbi.nlm.nih.gov/41228430/
- https://univ-paris-dauphine.hal.science/LBFA/cea-04773011v1
- https://trial.medpath.com/clinical-trial/f501a82685e98aff/pactr202004826694476-glycemic-control-laser-therapy-type-2-diabetes
- https://www.ncbi.nlm.nih.gov/books/NBK532263/
- https://pubmed.ncbi.nlm.nih.gov/9036661/
- https://pubmed.ncbi.nlm.nih.gov/39667415/
- https://pubmed.ncbi.nlm.nih.gov/37418658/
- https://pubmed.ncbi.nlm.nih.gov/33471046/
- https://pubmed.ncbi.nlm.nih.gov/38941162/
- https://pubmed.ncbi.nlm.nih.gov/19405857/
- https://pubmed.ncbi.nlm.nih.gov/31327162/
- https://pubmed.ncbi.nlm.nih.gov/34406235/
- https://vidm.org/event/23-radiant-beginnings-illuminating-pregnancy-health-with-light-therapy-for-midwives/
- https://pubmed.ncbi.nlm.nih.gov/40722630/
- https://www.familydoctor.cn/news/hongguang-liaofazhiliao-qiaobenjiazhuangxianyan-liangxiang-renti-yanjiu-qudechenggong-264726.html
- https://clinicaltrials.gov/study/NCT06735040
- https://library.nih.go.kr/ncmiklib/search/Retrieve.do?dbid=edb&an=177395423&highlight=AND&edsCnt=75&kwd=
- https://www.ncbi.nlm.nih.gov/books/NBK507829/
- https://pubmed.ncbi.nlm.nih.gov/3703162/
- https://pubmed.ncbi.nlm.nih.gov/3938791/
- https://pubmed.ncbi.nlm.nih.gov/28801854/
- https://pubmed.ncbi.nlm.nih.gov/30883832/
- https://trial.medpath.com/clinical-trial/f501a82685e98aff/pactr202004826694476-glycemic-control-laser-therapy-type-2-diabetes
- https://library.nih.go.kr/ncmiklib/search/Retrieve.do?dbid=edb&an=177395423&highlight=AND&edsCnt=75&kwd